Compare TSAT & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSAT | CRMD |
|---|---|---|
| Founded | 1969 | 2006 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.5M | 695.9M |
| IPO Year | 2021 | 2009 |
| Metric | TSAT | CRMD |
|---|---|---|
| Price | $37.42 | $7.87 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $37.00 | $14.83 |
| AVG Volume (30 Days) | 202.6K | ★ 1.2M |
| Earning Date | 05-05-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 780.00 |
| EPS | N/A | ★ 0.43 |
| Revenue | N/A | ★ $311,709,000.00 |
| Revenue This Year | N/A | $0.30 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $18.72 |
| Revenue Growth | N/A | ★ 617.03 |
| 52 Week Low | $19.59 | $6.13 |
| 52 Week High | $59.12 | $14.96 |
| Indicator | TSAT | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 40.32 | 42.72 |
| Support Level | $28.22 | $7.50 |
| Resistance Level | $43.82 | $9.02 |
| Average True Range (ATR) | 2.61 | 0.34 |
| MACD | -0.02 | -0.07 |
| Stochastic Oscillator | 16.65 | 13.57 |
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.